Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent fourth-quarter results, is expected to ...

With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers. The life sciences tools and services sector supports the research, development, and commercialization of biotechnology ...

Pacific Biosciences' Q4'24 results were another disappointment, with revenue and margin misses, and 2025 guidance was notably below expectations. Underlying utilization growth (genetic data ...

MENLO PARK, CA – Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leader in laboratory analytical instruments with a market capitalization of $357.59 million, has entered into a ...

Ark Invest's fund bought Iridium Communications Inc. IRDM, Beam Therapeutics Inc. BEAM, Pacific Biosciences of California Inc. PACB and Absci Corp ABSI, while selling Illumina Inc. ILMN ...

MENLO PARK, CA – Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leader in laboratory analytical instruments with a market capitalization of $357.59 million, has entered into a significant ...

Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2.00. The company’s shares closed yesterday at $1.32.

In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stands against the pump and dump stocks. Day trading involves buying and selling stocks ...